May 10, 2017 Bio/Pharma/CRO

Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer

Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy The safety profile was consistent with what has been previously observed for TECENTRIQ Roche (SIX: RO, ROG; OTCQX:... Read more

May 10, 2017 Bio/Pharma/CRO

Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer

Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy The safety profile was consistent with what has been previously observed for TECENTRIQ Roche (SIX: RO, ROG; OTCQX:... Read more

May 8, 2017 Life Science Tools Product Launch

Roche launches AVENIO ctDNA Analysis Kits for Oncology Research

Basel, 08 May 2017 First blood-based distributed oncology tests covering all four mutation classes Three test choices provide accurate insights into different stages and types of cancer Streamlined testing generates results in five days Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global commercial launch of the AVENIO circulating tumor DNA (ctDNA) Analysis Kits, a... Read more

May 8, 2017 Clinical Research/Diagn. Life Science Tools Product Launch

Roche launches AVENIO ctDNA Analysis Kits for Oncology Research

Basel, 08 May 2017 Roche launches AVENIO ctDNA Analysis Kits for Oncology Research First blood-based distributed oncology tests covering all four mutation classes Three test choices provide accurate insights into different stages and types of cancer Streamlined testing generates results in five days Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global commercial launch of... Read more

May 4, 2017 PR/Corporate

Save the date: Roche Analyst Event at ISTH 2017

Basel, 04 May 2017 Save the date: Roche Analyst Event at ISTH 2017 Monday, 10 July 2017, 6:30pm CEST We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017. During the briefing, Roche will discuss new... Read more

April 28, 2017 PR/Corporate

Invitation to Roche Analyst Event at ASCO 2017

Basel, 28 April 2017 Invitation to Roche Analyst Event at ASCO 2017 Monday, 5 June 2017, 5:15pm CDT We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (2 – 6... Read more

April 26, 2017 Licensing, IP, and Legal Life Science Tools

BD Licenses Novel Molecular Indexing Technology to Roche

FRANKLIN LAKES, N.J., Apr. 26, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has non-exclusively licensed its patented stochastic labelling technology to Roche for multiple commercial applications. BD’s patented stochastic labelling technology incorporating molecular indexes (known also as UMIs or molecular barcodes), enables the... Read more

April 26, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis

Basel, 26 April 2017 New data at AAN reinforce clinical benefit of Roche’s OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis OCREVUS rapidly suppressed signs of disease activity in relapsing MS (RMS) patients In patients with early RMS – recently diagnosed and without prior treatment – OCREVUS was superior to Rebif® (interferon beta-1a) in... Read more

April 19, 2017 Acad, Gov/Utilities Bio/Pharma/CRO PR/Corporate

Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis

Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data on... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more